Divine Aleru, Microbiome Signatures Research Coordinator

This study links the Cu/Zn ratio with markers of disease activity in IBD, suggesting it as a potential biomarker for disease monitoring. It emphasizes the role of zinc and copper deficiencies in IBD progression.

The study reveals a higher prevalence of zinc deficiency in Crohn’s disease patients compared to healthy controls. While serum zinc levels did not differ significantly between groups, the increased deficiency rate in CD highlights the need for zinc monitoring and potential supplementation in these patients.

This study highlights the high prevalence of iron deficiency anemia (IDA) in Crohn’s disease patients and its association with worse hospitalization outcomes, including longer stays, higher costs, and more readmissions. The findings stress the need for early IDA screening and management in this population.

This study reveals altered fecal bile acid composition in IBD patients, especially UC, suggesting the potential of bile acids as biomarkers for disease severity and differentiation between UC and CD.

This study links gut microbiota dysbiosis with bile acid composition changes in Crohn’s disease. The altered microbial and bile acid profiles may play a significant role in disease progression, offering potential therapeutic avenues.

This review discusses succinate’s role in IBD pathogenesis, focusing on its dual role in inflammation and tissue repair. The review underscores the importance of microbiota-driven succinate regulation and explores potential therapeutic strategies targeting succinate metabolism in IBD.

This narrative review explores succinate’s dual immunoregulatory roles in IBD, examining how its concentration affects inflammation and tissue repair. The study discusses potential therapeutic strategies targeting succinate metabolism and its signaling pathways.

This review investigates how gut microbiota dysbiosis impacts metabolic functions and immune responses in inflammatory bowel disease (IBD), highlighting key microbial changes and therapeutic potential through microbiome manipulation.

This study reveals the significant role of gut microbiome and metabolome signatures in predicting infliximab response in Crohn’s Disease, suggesting that microbiome-based biomarkers could guide personalized treatment strategies.

This study highlights the complex relationship between the gut microbiota, the immune system, and intestinal health. It emphasizes how disruptions to this balance can lead to chronic diseases like inflammatory bowel disease.

This review examines the environmental and genetic factors influencing Crohn’s disease, offering insight into how these factors contribute to disease onset, progression, and management. The study highlights the increasing incidence in developing countries and the role of diet, smoking, and infections.

This study systematically reviews the use of AI-assisted capsule endoscopy for detecting lesions in Crohn’s disease. AI showed high diagnostic accuracy with a sensitivity of 94% and specificity of 97%, highlighting its potential to improve the diagnostic process, though more research is needed for validation.

This review examines how migration and environmental risk factors influence the onset and course of inflammatory bowel diseases (IBD), with a focus on migrant populations transitioning from low-incidence to high-incidence regions. It emphasizes the need for further studies on generational changes and environmental triggers of IBD.

This review explores environmental factors such as smoking, diet, and air pollution that influence the onset and progression of Crohn’s disease. It highlights the importance of smoking cessation and dietary adjustments in managing the disease.

This review investigates the ongoing debate over the potential role of Mycobacterium avium subspecies paratuberculosis in Crohn’s disease. Despite frequent detection in patients, MAP’s causative role remains unproven, with studies showing inconsistent results, particularly regarding treatment efficacy.

The study examines the debate surrounding Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease, with conflicting data on its role as a causative factor. Anti-MAP therapies show mixed results, highlighting the need for further investigation into MAP’s involvement in CD pathogenesis.

This review examines how microbial dysbiosis in the gut contributes to systemic autoimmune diseases like type 1 diabetes, MS, RA, and SLE. It emphasizes microbial influences on immune responses and suggests potential microbiome-based therapies.

This review discusses the role of gut microbiota dysbiosis in IBD, its interaction with intestinal barriers, and the potential of microbiota-targeted therapies like antibiotics, probiotics, and FMT in treating IBD.

This review focuses on the genetic and epigenetic factors that contribute to Inflammatory Bowel Disease (IBD), highlighting key genes and microbiome interactions, and their role in disease pathogenesis and treatment response.

This review explores immunomodulatory therapies for IBD, focusing on their impact on the gut-brain axis. It evaluates conventional and emerging treatments like biologics, FMT, and probiotics, emphasizing their role in improving IBD outcomes and addressing neuropsychiatric symptoms.

The review examines the relationship between gut microbiota, diet, and extrinsic stressors in promoting intestinal inflammation, with implications for managing IBD. It emphasizes the potential benefits of dietary changes and probiotics in restoring gut health and mitigating inflammation.

This review explores the genetic complexities of NOD2 in Crohn’s disease, emphasizing its role in the stricturing phenotype and the need for deeper research into rare variants and their functional impacts.

This review highlights the genetic and environmental factors influencing Crohn’s disease, including the role of NOD2 mutations, smoking, diet, and vitamin D deficiency. It underscores the need for personalized treatment strategies to manage this complex disease.

This review discusses the pathogenesis of osteoporosis in Crohn’s disease, focusing on the role of cytokines, glucocorticoids, and malnutrition. It emphasizes the importance of early detection and treatment strategies to prevent fractures and improve patient outcomes.